期刊
FEBS LETTERS
卷 582, 期 1, 页码 81-89出版社
WILEY
DOI: 10.1016/j.febslet.2007.11.018
关键词
AMP-activated protein kinase; metabolic syndrome; diabetes; metformin; thiazolidinedione; ventricular pre-excitation
资金
- Wellcome Trust Funding Source: Medline
Obesity, type 2 diabetes and the metabolic syndrome are disorders of energy balance, which the AMP-activated protein kinase (AMPK) regulates both at the cellular and whole body levels. AMPK switches cells from an anabolic state where nutrients are taken up and stored, to a catabolic state where they are oxidized. Drugs that activate AMPK indirectly (metformin and thiazolidinediones) are now the mainstay of treatment for type 2 diabetes, but more direct AMPK activators may have fewer side effects. However, activating mutations in AMPK can cause heart disease, and it will be important to look for adverse effects in the heart. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据